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Aims. Recent randomised controlled trials (RCTs) have shown a significant prognostic benefit of sodium-glucose cotransporter 2
(SGLT2) inhibitors in the cardiovascular (CV) profile of patients with diabetes. 'is systematic review and meta-analysis aim to
provide a concise evaluation of all the available evidence for the use of these agents in patients with heart failure (HF) regardless of
their baseline diabetes status.Methods and Results. PubMed, Web of Science, and Cochrane library databases were systematically
searched from inception until November 20th 2020. Eight studies consisting of 13,275 patients were included in the meta-analysis.
For the total population, SGLT2 inhibitors reduced the risk of all-cause mortality (HR: 0.83; 95% CI: 0.75–0.91; I2 0%), hos-
pitalisation for HF (HR: 0.68; 95% CI: 0.61–0.75; I2: 0%), CV death (HR: 0.82; 95% CI: 0.74–0.92; I2: 0%), and hospitalisation for
HF or CV death (HR: 0.72; 95% CI: 0.66–0.78; I2: 0%). Subgroup analyses of the total population according to the diabetes status
showed that SGLT2 inhibitors significantly reduced the risk of hospitalisation for HF (HR: 0.68; 95% CI: 0.61, 0.75; I2: 0%), as well
as the risk of hospitalisation for HF or CV death (HR: 0.72; 95% CI: 0.66, 078; I2: 0%) and CV death (HR: 0.82; 95% CI: 0.74, 0.91;
I2: 0%). Conclusions. 'e results of this meta-analysis confirm the growing evidence in the literature of the favourable profile of
SGLT2 inhibitors in cardiovascular outcomes andmortality in patients with heart failure regardless of the baseline diabetes status.
'is systematic review has been registered with PROSPERO (CRD42021224777).
1. Introduction
Over the recent years, large randomised controlled trials have
demonstrated that sodium-glucose cotransporter 2 (SGLT2)
inhibitors improve cardiovascular outcomes irrespective of
diabetes, including risk of hospitalisation for heart failure
(HHF), cardiovascular death, and all-cause mortality [1–4].
Being a glucose-loweringmedication, SGLT2 inhibitors proved
to have a significant role in reducing major adverse cardio-
vascular outcomes and hospitalisation for heart failure initially
in patients with diabetes. 'e magnitude of their impact has
been subsequently shown to be potentially independent—or, at
least, separated—from their glucose-lowering value with a few
hypotheses behind the exact mechanisms of their actions [5, 6].
'e rapid accumulation of such evidence showing their
favourable impact has triggered further research exploring their
potential on cardiovascular outcomes and mortality in larger
cohorts, not necessarily limited to diabetic populations. In
response to this, two large randomised controlled studies in-
vestigated the impact of SGLT2 inhibitors in heart failure
patients, with the cohort being comprised of patients with and
without diabetes [7, 8].
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With an increasing number of trials reporting on SGLT2
inhibitors in patients with and without diabetes, the goal of
this systematic review and meta-analysis is to provide a
concise evaluation of all the available evidence so far and
analyse the data from the existing studies that focus on
patients with heart failure, so as to better comprehend the
clinical implications of the use of SGLT2 inhibitors. Addi-
tionally, we a priori planned to analyse the existing evidence
depending on the diabetic status with the goal to determine
the efficacy of SGLT2 both in the diabetic population and in
heart failure patients without diabetes.
2. Methods
'is is a systematic review and meta-analysis conducted and
reported according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analysis (PRISMA) guide-
lines. It has been submitted and registered with PROSPERO
(registration number: CRD42021224777).
2.1. Search Strategy. PubMed, Web of Science, and
Cochrane library databases were systematically searched
from inception until November 20th 2020. 'e key terms
used for the search were (“SGLT2” or “Sodium-glucose
cotransporter-2 inhibitors” or “canagliflozin” or “dapagli-
flozin” or “empagliflozin” or “ertugliflozin”) and “heart
failure.”
2.2. Study Selection. After removing duplicates, all the
remaining studies were screened at the title/abstract level.
Our inclusion criteria were as follows:
(1) Observational or randomised controlled studies
comparing SGLT2 inhibitors with placebo
(2) Included adults (>18 years old)
(3) Included patients diagnosed with heart failure, either
with prespecified echocardiographic parameters
(ejection fraction) or investigator-reported
(4) Assessed mortality or clinical outcomes in patients
with heart failure taking SGLT2 inhibitors
(5) Studies which include imaging or blood biomarker
parameters as outcomes that were included in the
systematic review but not the meta-analysis
'e selected studies underwent full-text screening. 'is
process was performed by 3 independent investigators
(R. C., M. D., and V. T.). Any conflicts were resolved by
discussion, after which consensus was achieved. 'e study
selection process is depicted in Figure 1 in Supplementary
Materials.
2.3. Data Extraction. Two investigators (V. T. and R. B.)
independently extracted the data from the selected studies
using prespecified collection forms. 'e data extracted in-
cluded type and characteristics of the study, number of
patients on each group, number of diabetic and nondiabetic
patients (where applicable), hazard ratios and confidence
intervals for hospitalisation for heart failure (HHF), car-
diovascular (CV) mortality, and all-cause mortality. 'e
main outcomes of interest were all-cause mortality, CV
mortality, and HHF. In studies that included both HF and
non-HF patients, the data for the HF group with reduced
ejection fraction was extracted from the prespecified sub-
group analysis given in the respective study. Additionally,
wherever possible, the outcomes were evaluated in subgroup
analyses that included (1) patients with diabetes and (2)
patients without diabetes.
2.4. Data Analysis. 'e hazard ratios and 95% CI that were
given in each study were used for the meta-analysis. A
random-effects model with inverse-variance weights was
used to combine the effect measures from all studies on a
logarithmic scale. Wherever possible, subgroup analysis in
diabetic versus nondiabetic patients was performed. Sta-
tistical heterogeneity was assessed using the I2 statistic. 'e
statistical analyses were conducted using the Review Man-
ager (RevMan) software (version 5.3. Copenhagen: 'e
Nordic Cochrane Centre, 'e Cochrane Collaboration,
2014).'e statistical significance was defined as p< 0.05.'e
between-study variance component was estimated using the
DerSimonian and Laird method, which is the default ap-
proach of the software used for this meta-analysis [9].
3. Results
Out of the 86 studies that underwent full-text evaluation, a
total of 8 studies including 13,275 participants were in-
cluded. A total of 6,877 of these participants were in the
SGLT2 group, while 6,398 were in the placebo group.
Dapagliflozin was used in three Randomised Control Trials
(RCT), empagliflozin in two RCTs, and canagliflozin,
sotagliflozin, and ertugliflozin were used in one RCT each.
Some three studies included patients with and without di-
abetes, two of which provided hazard ratios for cardiovas-
cular and mortality outcomes that were used in the statistical
analyses [7, 8]. 'e nondiabetic cohort is comprised of 4,576
patients, out of which 2,284 were in the SGLT2 group and
2,292 were in the placebo group. While the majority of the
studies had prespecified left ventricular ejection fraction
(LVEF) in their inclusion criteria, two studies had “inves-
tigator reported HF” with no prerequisite for EF for in-
clusion in the study, while one required specific NT-proBNP
level along with previous hospitalisation for HF. 'ree
studies included patients with EF≤ 40%, two studies in-
cluded patients with EF≤ 45% and EF > 45%, one study
reports a median baseline EF of 35% and two studies did not
have prespecified baseline ejection fraction of the heart
failure population in their inclusion criteria. 'e two studies
(DECLARE-TIMI 58 & VERTIS CV) that have included
patients with both EF≤ 45% and EF> 45% have provided
separate hazard ratios for the two groups. In order to
maintain a more homogeneous group of baseline charac-
teristics, the hazard ratios given for the group with the
EF< 45% were used in the meta-analyses of the efficacy
endpoints for the total population examined in our review
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and in the subgroup analysis according to the baseline di-
abetes status. However, a further subgroup analysis was
performed to examine the impact of SGLT2 inhibitors in
patients with EF≤ 45% compared with their impact in pa-
tients with EF> 45%. Table 1 summarises the characteristics
of all the studies included in the meta-analysis with the
available number of cardiovascular events provided from
each study, while Supplementary Table 1 summarises the
cardiovascular outcomes for patients with and without di-
abetes from the studies that investigated these cohorts
separately. Cochrane collaboration’s tool was used for as-
sessment of risk of bias to assess the randomised controlled
studies (Supplementary Table 2).
3.1. Efficacy Endpoints. In the analyses that included all the
participants (regardless of diabetes status), the use of SGLT2
inhibitors was associated with significantly reduced risk of
all-cause mortality (HR� 0.83, 95% CI, 0.75–0.91; I2 0%)
(Figure 1), hospitalisation for heart failure (HHF)
(HR� 0.68, 95% CI, 0.61–0.75; I2 0%) (Figure 2), CV death
(HR� 0.82, 95% CI, 0.74–0.92; I2 0%) (Figure 3), and
hospitalisation for heart failure or CV death (HR� 0.72, 95%
CI, 0.66–0.78; I2 0%) (Figure 4) compared with placebo.
Subgroup analysis of the total population according to the
diabetes status showed that SGLT2 inhibitors significantly
reduced the risk of HHF both in patients with and without
diabetes (HR� 0.68, 95% CI: 0.60–0.76; I2 0% and HR� 0.69,
95% CI: 0.56–0.84; I2 0%, respectively) (Figure 5), as well as
the risk of HHF or CV death (HR� 0.70, 95% CI: 0.64–0.77;
I2 0% and HR� 0.75, 95% CI: 0.66–0.87; I2 0%, respectively)
(Figure 6).'e favourable impact of SGLT2 inhibitors on the
outcome of CV death alone was significant in the partici-
pants with diabetes although it did not reach the level of
statistical significance in the participants without diabetes
(Figure 7). Additionally, subgroup analysis according to
baseline EF was performed from the data available from the
two studies (DECLARE-TIMI 58 & VERTIS CV) that
stratified patients according to this. SGLT2 inhibitors did
not have a significant impact on all-cause mortality
(HR� 0.88, 95% CI: 0.67–1.14; I2 45%) (Supplementary
Figure 2) or cardiovascular death (HR� 0.95, 95% CI:
0.63–1.44; I2 65%) (Supplementary Figure 3) with no sig-
nificant differences between the two groups. However,
SGLT2 inhibitors significantly reduced the risk of hospi-
talisation for heart failure or CV death (HR 0.78, 95% CI:
0.65–0.94; I2 9%) with more pronounced effect on the group
of heart failure with reduced ejection fraction, whereas in
participants with EF> 45%, the favourable impact of SGLT2
inhibitors did not reach the level of statistical significance
(Supplementary material Figure 4).
Funnel plots for unadjusted all-cause mortality (Sup-
plementary Figure 5) and hospitalisation for heart failure
(Supplementary Figure 6) were used to assess publication
bias with no evidence of significant publication bias.
3.2. .e Impact of SGLT2 on LV Function and BNP. A rel-
atively small number of studies have been published so far
investigating the impact of SGLT2 inhibitors on LV function
and dimensions as assessed by imaging parameters, bio-
markers (NT-proBNP or BNP), exercise capacity, symptom
improvement, and quality of life in patients with heart
failure. Table 2 summarises these studies along with their
main characteristics and outcomes of interest.
EMPA-TROPISM is the only study so far investigating
the effect of SGLT2 exclusively in nondiabetic patients [10].
Comprised of 84 participants, it showed that empagliflozin
had a significantly positive impact on LV function and
remodelling as well as on the quality of life compared to
placebo. On the other hand, the EMPIRE-HF study, which
included 190 diabetic and nondiabetic patients, did not show
significant differences between empagliflozin and placebo in
any of the endpoints investigated (NT-proBNP, activity level
and quality of life/symptomatic improvement) 3months
after initiation of the treatment [11]. While this RCTdid not
study LV function or volumes by any means of imaging, it is
notable that the follow-up period was relatively short
(3months), which differentiates it from the rest of the
studies. Apart from the relatively short follow-up period, the
participants of this study were patients with a relatively
milder phenotype of heart failure with better baseline status
and functional capacity and lower baseline NT-proBNP
levels [11].
LV function was assessed by echocardiography in some
of the studies and by CMR in others. From the echocar-
diographic studies, it was noted that SGLT2 inhibitors did
have a positive impact on diastolic function. In two of the
three studies, the majority of the patients had HF with
preserved ejection fraction [12, 13], while the third study
included a small number of patients (twelve) with advanced/
drug refractory heart failure [14]. Even in this small cohort
with advanced disease, there was an improvement in the E/e’
ratio; however, this did not reach the level of statistical
significance (p value given as 0.06).
From the studies that utilised CMR, it may be argued
that SGLT2 favours cardiac remodelling and improvement
in LV volumes; however, results are not consistent. More
specifically, the LV end-diastolic volume (LVEDV) was
assessed with the use of CMR in three RCTs: SUGAR-DM-
HF, EMPA-TROPISM, and REFORM [10, 15, 16]. SUGAR-
DM-HF and EMPA-TROPISM included a combined
number of 189 patients and demonstrated a significant
improvement of the LVEDV in the SGLT2 arm compared to
placebo [10, 15]. Remarkably, this positive effect was also
noted in the nondiabetic cohort that the EMPA-TROPISM
study included [10]. 'e REFORM study included 56 pa-
tients in total, and after 12 months of follow-up, the in-
vestigators did not find significant differences in the LV
volumes between the SGLT2 and placebo groups [16]. It
should be noted that the patient cohort consisted of diabetic
patients with mild HF symptoms on modest doses of loop
diuretics. Nevertheless, in the same study, a significant re-
duction in the diuretic requirements was noted in the SGLT2
group.
'e evidence regarding BNP/NT-proBNP is somewhat
inconsistent, with some of the studies showing improvement
[13–15] and others demonstrating no substantial changes
between the two groups [12, 17]. 'is could be explained by
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SGL T2 Placebo Hazard Ratio 
IV, Random, 95% CI
Hazard Ratio 
IV, Random, 95% CIStudy or Subgroup log[Hazard Ratio] SE Total Total Weight 
CANVAS -0.6733 803 658 5.6% 0.51 [0.33, 0.79]
DEFINE-HF
DAPA-HF -0.3567 0.0872 2373 2371 36.2% 0.70 [0.59, 0.83]
DECLARE-TIMI 58 -0.4463 0.2029 318 353 6.7% 0.64 [0.43, 0.95]
EMPAREG
-0.1744 0.4323 131 132 1.5% 0.84 [0.36, 1.96]
EMPEROR-REDUCED
-0.2877 0.2277 462 244 5.3% 0.75 [0.48, 1.17]
SOLOIST-WHF
-0.3567 0.0959 1863 1867 29.9% 0.70 [0.58, 0.84]
-0.4463 0.1363 608 614 14.8% 0.64 [0.49, 0.84]
Total (95% Cl) 6558 6239 100.0% 0.68 [0.61, 0.75]
Heterogeneity: Tau2 = 0.00; Chi2 = 2.59, df = 6 (P = 0.86); I2 = 0%
0.2 0.5 1 2 5Test for overall effect: Z = 7.38 (P < 0.0001)
Favours SGLT2 Favours placebo 
0.2221
Figure 2: Effect of SGLT2 inhibitors versus placebo on hospitalisation for heart failure for the total population.
SGL T2 Placebo Hazard Ratio 
IV, Random, 95% CI
Hazard Ratio 
IV, Random, 95% CIStudy or Subgroup log[Hazard Ratio] SE Total Total Weight 
CANVAS -0.3285 803 658 9.9% 0.72 [0.51, 1.02]
EMPAREG
DAPA-HF -0.1985 0.0881 2373 2371 39.4% 0.82 [0.69, 0.97]
DECLARE-TIMI 58 -0.5978 0.2454 318 353 5.1% 0.55 [0.34, 0.89]
VERTIS CV
-0.3425 0.2559 462 244 4.7% 0.71 [0.43, 1.17]
EMPEROR-REDUCED -0.0834 0.1042 1863 1867 28.1% 0.92 [0.75, 1.13]
SOLOIST-WHF -0.1744 0.189 608 614 8.6% 0.84 [0.58, 1.22]
-0.0408 0.266 319 159 4.3% 0.96 [0.57, 1.62]
Total (95% Cl) 6746 6266 100.0% 0.82 [0.74, 0.92]
Heterogeneity: Tau2 = 0.00; Chi2 = 5.10, df = 6 (P = 0.53); I2 = 0% 0.2 0.5 1 2 5Test for overall effect: Z = 3.56 (P = 0.0004)
Favours SGLT2 Favours placebo 
0.1759
Figure 3: Effect of SGLT2 inhibitors versus placebo on cardiovascular death for the total population.
SGL T2 Placebo Hazard Ratio 
IV, Random, 95% CI
Hazard Ratio 
IV, Random, 95% CIStudy or Subgroup log[Hazard Ratio] SE Total Total Weight 
CANVAS -0.4943 803 658 8.4% 0.61 [0.46, 0.81]
EMPAREG
DAPA-HF -0.2877 0.073 2373 2371 32.7% 0.75 [0.65, 0.87]
DECLARE-TIMI 58 -0.478 0.1635 318 353 6.5% 0.62 [0.45, 0.85]
VERTIS CV
-0.3285 0.186 462 244 5.0% 0.72 [0.50, 1.04]
EMPEROR-REDUCED -0.2877 0.073 1863 1867 32.7% 0.75 [0.65, 0.87]
SOLOIST-WHF -0.4005 0.1293 608 614 10.4% 0.67 [0.52, 0.86]
-0.2744 0.2035 319 159 4.2% 0.76 [0.51, 1.13]
Total (95% Cl) 6746 6266 100.0% 0.72 [0.66, 0.78]
Heterogeneity: Tau2 = 0.00; Chi2 = 3.16, df = 6 (P = 0.79); I2 = 0%
0.2 0.5 1 2 5Test for overall effect: Z = 7.92 (P < 0.00001)
Favours SGLT2 Favours placebo 
0.144
Figure 4: Effect of SGLT2 inhibitors versus placebo on hospitalisation for heart failure or cardiovascular death for the total population.
SGL T2 Placebo Hazard Ratio 
IV, Random, 95% CI
Hazard Ratio 
IV, Random, 95% CIStudy or Subgroup log[Hazard Ratio] SE Total Total Weight 
CANVAS -0.3567 803 658 9.1% 0.70 [0.51, 0.96]
DAPA-HF -0.1863 0.0797 2373 2371 37.6% 0.83 [0.71, 0.97]
DECLARE-TIMI 58 -0.5276 0.1983 318 353 6.1% 0.59 [0.40, 0.87]
EMPAREG -0.2357 0.2134 462 244 5.2% 0.79 [0.52, 1.20]
EMPEROR-REDUCED -0.0834 0.0908 1863 1867 29.0% 0.92 [0.77, 1.10]
SOLOIST-WHF -0.1985 0.168 608 614 8.5% 0.82 [0.59, 1.14]
VERTIS CV -0.0408 0.2314 319 159 4.5% 0.96 [0.61, 1.51]
Total (95% Cl) 6746 6266 100.0% 0.83 [0.75, 0.91]
Heterogeneity: Tau2 = 0.00; Chi2 = 5.81, df = 6 (P = 0.45); I2 = 0%
0.2 0.5 1 2 5Test for overall effect: Z = 3.89 (P = 0.0001)
Favours SGLT2 Favours placebo 
0.1616
Figure 1: Effect of SGLT2 inhibitors versus placebo on all-cause mortality for the total population.
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the discrepancies in the baseline characteristics of the
participants in addition to the different follow-up periods
and methodology in each study.
Despite the fact that each of the aforementioned studies
comprised a relatively small number of patients and in-
vestigated LV function and parameters by different imaging
modalities (echocardiography or CMR), it can be argued
that even in this heterogeneous group, there is a general
trend towards improvement of diastolic function and LV
volumes in the SGLT2 group, even if these did not always
reach the level of statistical significance. Further research
with large randomised controlled trials would be beneficial
in portraying the impact of SGLT2 inhibitors on LV
function, tissue characterisation, and cardiac remodelling.
4. Discussion
'e present meta-analysis, the largest to date, shows that the
use of SGLT2 inhibitors is associated with reduction in the
risk of hospitalisation for heart failure, cardiovascular death,
and all-cause mortality in patients with heart failure pri-
marily with reduced ejection fraction. In subgroup analyses
SGLT2 Placebo
Study or Subgroup log[Hazard Ratio] SE Total 
Hospitalisation for Heart Failure - Non Diabetic Population
DAPA-HF -0.462 0.1387 1298 
EMPEROR-REDUCED -0.2744 0.1468 936 
Subtotal (95% CI) 2234
Heterogeneity: Tau2 = 0.00; Chi2 = 0.86, df = 1 (P = 0.35); I2 = 0%
Test for overall effect: Z = 3.70 (P = 0.0002)
Hospitalisation for Heart Failure - Diabetic Population
CANVAS -0.6733 0.2221 803
DAPA-HF -0.2744 0.1122 1075
DECLARE-TIMI 58 -0.4463 0.2029 318
DEFINE-HF -0.1744 0.4323 131
EMPAREG -0.2877 0.2277 462
EMPEROR-REDUCED -0.4308 0.1339 927
SOLOIST-WHF -0.4463 0.1363 608
Subtotal (95% CI) 4324
Heterogeneity: Tau2 = 0.00; Chi2 = 3.48, df = 6 (P = 0.75); I2 = 0%
Heterogeneity: Tau2 = 0.00; Chi2 = 4.36, df = 8 (P = 0.82); I2 = 0%
Test for overall effect: Z = 6.27 (P < 0.00001)
Total (95% CI) 6558
Test for overall effect: Z = 7.28 (P < 0.00001)















IV, Random, 95% CI
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0.2 0.5 1 2 5
Favours SGLT2 Favours placebo
Figure 5: Subgroup analysis of the treatment effect SGLT2 inhibitors on hospitalisation for heart failure depending on baseline diabetes
status.
SGLT2 Placebo
Study or Subgroup log[Hazard Ratio] SE
HHF or CV death - Non Diabetic Population 
DAPA-HF -0.3147 0.1001 1298
EMPEROR-REDUCED -0.2485 0.1009 936
Subtotal (95% CI) 2234
Heterogeneity: Tau2 = 0.00; Chi2 = 0.22, df = 1 (P = 0.64); I2 = 0%
Test for overall effect: Z = 3.97 (P < 0.0001)
HHF or CV death - Diabetic population 
CANVAS -0.4943 0.144 803
DAPA-HF -0.2877 0.089 1075
DECLARE-TIMI 58 -0.478 0.1635 318
EMPAREG -0.3285 0.186 462
EMPEROR-REDUCED -0.3285 0.093 927
SOLOIST-WHF -0.4005 0.1293 608
VERTIS CV -0.2744 0.2035 319
Subtotal (95% CI) 4512
Heterogeneity: Tau2 = 0.00; Chi2 = 2.46, df = 6 (P = 0.87); I2 = 0% 
Test for overall effect: Z = 7.44 (P < 0.00001) 
Total (95% CI) 6746
Heterogeneity: Tau2 = 0.00; Chi2 = 3.39, df = 8 (P = 0.91); I2 = 0%
Test for overall effect: Z = 8.39 (P < 0.00001) 
Test for subgroup differences: Chi2 = 0.72, df = 1 (P = 0.40). I2 = 0% 
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Favours SGLT2 Favours placebo
Figure 6: Subgroup analysis of the treatment effect SGLT2 inhibitors on hospitalisation for heart failure or cardiovascular death depending
on baseline diabetes status.
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SGLT2 Placebo Hazard Ratio 
IV, Random, 95% CITotal Total Weight
1298
936
SElog[Hazard Ratio]Study or Subgroup
Cardiovascular Death - Non Diabetic Population
DAPA-HF -0.1625 0.1291 
EMPEROR-REDUCED -0.0834 0.1542 
Subtotal (95% CI) 2234
Heterogeneity: Tau2 = 0.00; Chi2 = 0.15, df = 1 (P = 0.69); I2 = 0% 
Test for overall effect: Z = 1.31 (P = 0.19) 
Cardiovascular Death - Diabetic Population
CANVAS -0.3285 0.1759 803
DAPA-HF -0.2357 0.1155 1075
DECLARE-TIMI 58 -0.5978 0.2454 318
EMPAREG -0.3425 0.2559 462
EMPEROR-REDUCED -0.0834 0.1322 927
SOLOIST-WHF -0.1744 0.189 608
VERTIS CV -0.0408 0.266 319
Subtotal (95% CI) 4512
Heterogeneity: Tau2 = 0.00; Chi2 = 4.57, df = 6 (P = 0.60); I2 = 0% 
Test for overall effect: Z = 3.48 (P = 0.0005) 
Total (95% CI) 6746
Heterogeneity: Tau2 = 0.00; Chi2 = 5.37, df = 8 (P = 0.72); I2 = 0% 
Test for overall effect: Z = 3.63 (P = 0.0003) 
Test for subgroup differences: Chi2 = 0.65, df = 1 (P = 0.42). I2 = 0% 
1307 17.6% 0.85 [0.66, 1.09]
938 12.3% 0.92 [0.68, 1.24]
2245 30.0% 0.88 [0.72, 1.07]
658 9.5% 0.72 [0.51, 1.02]
1064 22.0% 0.79 [0.63, 0.99]
353 4.9% 0.55 [0.34, 0.89]
244 4.5% 0.71 [0.43, 1.17]
929 16.8% 0.92 [0.71, 1.19]
614 8.2% 0.84 [0.58, 1.22]
159 4.1% 0.96 [0.57, 1.62]
4021 70.0% 0.80 [0.70, 0.91]
6266 100.0% 0.82 [0.74, 0.91]
Hazard Ratio 
IV, Random, 95% CI
0.2 0.5 21 5
Favours SGLT2 Favours placebo
Figure 7: Subgroup analysis of the treatment effect SGLT2 inhibitors on cardiovascular death depending on baseline diabetes status.
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stratified by the presence of diabetes, it is demonstrated that
SGLT2 inhibitors provide consistent benefit on cardiovas-
cular outcomes regardless of the baseline diabetes status.
Our data are in agreement with previous evidence that
supports the prognostic value of SGLT2 in cardiovascular
outcomes and mortality. Crucially, our findings highlight
the importance of this drug group in the patients with heart
failure regardless of diabetes status, revealing in this way that
the potential therapeutic benefit in this population cohort
could be invaluable.
4.1. Current Evidence and Recommendations. Previous large
RCTs have shown remarkable benefits of SGLT2 specifically
in cardiovascular outcomes in the diabetic population
[18–20]. 'ese results drew the attention to one or more
potentially unrevealed thus far cardioprotective mechanisms
of SGLT2 inhibitors that make it unique in the world of oral
antidiabetic medications. Interestingly, the impact of SGLT2
inhibitors on cardiovascular outcomes does not seem to be
directly related with their glucose-lowering efficacy [5].
Since there are now accumulating evidence supporting that
the cardioprotective mechanisms are not associated with the
glycemic control, the focus has been shifted to using these
agents to patients regardless of their baseline diabetes status.
Previous studies that have investigated the effect of SGLT2
inhibitors in nondiabetic cohorts have so far demonstrated
positive results [7, 8, 10, 21]. 'e rapidly accumulating
evidence of the substantial favourable impact of these agents





































(E/e’) and GLS as
well as LAVi. No
significant changes































































RCT, randomised controlled trial; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; EF, ejection
fraction; DM, diabetes mellitus; LVESVi, left ventricular end systolic volume indexed; LVEDVi, left ventricular end-diastolic volume indexed; GLS, global
longitudinal strain; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass indexed; LAVi, left atrial volume indexed; 6MWT, 6-minute walk test;
KCCQ-TSS, Kansas City Cardiomyopathy Questionnaire Total Symptom Score; KCCQ-OSS, Kansas City Cardiomyopathy Questionnaire Overall Summary
Score; CPET, cardiopulmonary exercise test; E/E’, ratio of early diastolic peak velocity of Doppler transmitral flow to early diastolic mitral annular velocity;
TRPG, pressure gradient of tricuspid regurgitation; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide.
8 Cardiology Research and Practice
cardiovascular death has led in their inclusion in the latest
recommendations for the management of patients with
heart failure [22]. Notably, given the results of DAPA-HF
and EMPEROR-Reduced trials, dapagliflozin and empagli-
flozin are now recommended in symptomatic patients with
HF and reduced EF on optimal treatment, regardless of the
presence of diabetes [7, 8, 22].
4.2. Potential Mechanisms of Action. While the exact path-
ophysiological process remains to be fully understood, there
are several hypotheses that investigate the cardiometabolic
profile of these agents. Some of the benefits observed most
notably particularly in the HF population could be explained
by the natriuresis and osmotic diuresis that these agents
promote [5, 23]. 'is, subsequently, results in improvement
of the left ventricular loading conditions by a reduction in
the preload. While one may argue that this is a feature of all
the commonly used diuretics, it has been noted that SGLT2
inhibitors do not reduce the intravascular volume asmuch as
the common diuretics but instead target rather selectively
the interstitial fluid, with a greater reduction in the extra-
cellular fluid and no major impact on organ perfusion
[24, 25]. Interestingly, in a small study by Griffin et al., it was
demonstrated that empagliflozin resulted in natriuresis
which was independent of the glucose load, indicating a
direct natriuretic effect distinct from the osmotic diuresis
[26]. Additionally, in contrast with the loop diuretics, SGLT2
inhibitors promote uricosuria and can reverse diuretic-in-
duced hyperuricaemia, another contributing factor to their
cardiovascular protective effects [27].
SGLT2 inhibitors have also been shown to reduce the
blood pressure without increasing the heart rate and
therefore improve the myocardial workload [28]. 'e
pathophysiology behind this mechanism is not delineated
yet; nevertheless, there is data to suggest that reduction in
arterial stiffness and improvement on vascular resistance
may play a significant role [5, 6, 28].
'e action of SGLT2 inhibitors on a cellular level is
surprising as they induce a state that mimics starvation [29].
As a result, there is activation of signaling pathways that
involve important enzymes such as the sirtuin 1 (SIRT1) and
the adenosine monophosphate-activated protein kinase
(AMPK), both of which attenuate oxidative stress and in-
flammation and promote oxidation of fatty acids resulting in
ketonaemia [29, 30]. Additionally, the activation of SIRT1
leads to stimulation of erythropoietin synthesis and eryth-
rocytosis, which has been found to be one of the factors
contributing to the significant cardiovascular benefits of
SGLT2 inhibitors [31, 32].
Furthermore, SGLT2 inhibitors improve insulin sensi-
tivity and glycemic control. With reduced requirements in
insulin, SGLT2 inhibitors promote weight loss which also
contributes to lower blood pressure [33]. While it could be
argued that these effects are reflected on the improvement of
diastolic function and filling pressure parameters noted in
the echocardiographic studies investigating the impact of
these agents on LV function, further research on this matter
is required to prove this hypothesis.
Another promising emerging feature of SGLT2 inhibi-
tors is their antifibrotic impact on the heart [34, 35]. Pre-
clinical research data have demonstrated that empagliflozin
directly attenuates cardiac myofibroblast activity and col-
lagen remodelling [34], while dapagliflozin also diminishes
the process of myocardial fibrosis after myocardial infarction
[35]. It will be of great clinical interest to assess if these
research data are in accordance with findings from CMR
studies focusing on the left ventricular tissue
characterisation.
Undoubtedly, CMR holds an important role in the as-
sessment of LV function, and it can provide invaluable
information about the impact of the SGLT2 inhibitors on left
ventricular function and remodelling. Recently, the EMPA-
HEART CardioLink-6 randomised placebo-controlled trial
thoroughly investigated data from 74 patients with diabetes
type 2 with coronary artery disease that underwent a
comprehensive CMR study [36]. It demonstrated a signif-
icant reduction in myocardial extracellular compartment
volume (ECV), indexed extracellular compartment volume
(iECV), and indexed LV mass (LVMi) after 6months of
treatment with empagliflozin compared with placebo. In the
same study, tissue remodelling biomarkers were also mea-
sured at baseline and at 6months, with no significant dif-
ference found between the SGLT2 and placebo groups. It has
to be noted however that this study was not powered to
detect differences in these and that in this patient cohort the
baseline levels of these biomarkers were actually in the
normal range. 'erefore, further studies, including ideally
patients with heart failure, are required to obtain detailed
information that could provide a new perspective in the
mechanism of action of SGLT2 inhibitors on the diseased
myocardium.
Independently of the mode of action, our meta-analysis
conclusively confirms that SGLT2 inhibitors have a bene-
ficial effect in patients with HF independently of the diabetes
status, reducing mortality by 17%, and hospitalisation for
heart failure by almost a third, supporting the need for
increased utilisation in patients with reduced LVEF.
5. Limitations
'is study has potential limitations that should be consid-
ered. Firstly, not all the randomised controlled trials have
published the necessary subgroup data for all the endpoints.
'erefore, some of these trials were not included in the
analysis of individual endpoints. Secondly, in this meta-
analysis we included RCTs that performed subgroup analysis
depending on the HF status, regardless of their definition of
HF. While most of the studies gave prespecified EF in their
inclusion criteria, some studies had “investigator-reported
HF.” Additionally, in order to maintain homogeneity, the
data published for the cohort with the reduced EF were used
in the meta-analyses of the efficacy endpoints for the total
population, as this cohort represents the vast majority of the
participants in the RCTs analysed in this meta-analysis. We
performed subgroup analysis of the main endpoints
according to the EF, when these data were provided.
Whereas the level of heterogeneity for the analyses of the
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endpoints for the total population was insignificant as
assessed by I2 of 0%, there was moderate to substantial
heterogeneity in the subgroup analyses of endpoints
according to EF as evidenced by an I2 that ranged between
9% and 65%. It has to be acknowledged that the subgroup
analysis of endpoints according to baseline EF was com-
prised of only two studies and a small number of individuals,
and this could be one of the reasons for the higher level of
heterogeneity. Finally, we acknowledge that assessment of
publication bias with the use of funnel plots is less reliable
when the meta-analysis is comprised of less than ten studies
in total.
6. Conclusion
It is without a doubt that SGLT2 inhibitors provide prog-
nostic benefit in patients with heart failure, regardless of the
exact mechanism of action. 'e recent large RCTs have
shown that this positive impact is expanded in patients
without diabetes. 'is systematic review and meta-analysis
provide robust summative evidence of the effectiveness of
these agents in patients with heart failure regardless of the
diabetes status. Our results also suggest that they are likely to
be more effective in patients with reduced LVEF. Data on
their mechanism is limited with imaging studies performed
to date providing conflicting information. Further studies
are needed to better understand their mechanisms of action
and their long-term impact on LV function and biomarkers
as well as the heart failure phenotype that will benefit most
from them. Nevertheless, given the unique pathophysio-
logical profile of SGLT2 inhibitors and their significant
benefit in cardiovascular profile, they have an invaluable role
in the management of patients with heart failure. 'e role of
CMR is critical in facilitating volumes and tissue charac-
terisation, and it will take a prominent role in future research
studies.
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[22] P. M. Seferović, A. J. S. Coats, P Ponikowski et al., “European
Society of Cardiology/Heart Failure Association position
paper on the role and safety of new glucose-lowering drugs in
patients with heart failure,” European Journal of Heart Failure,
vol. 22, pp. 196–213, 2020.
[23] C. S. P. Lam, C. Chandramouli, V. Ahooja, and S. Verma,
“SGLT-2 inhibitors in heart failure: Current management,
unmet needs, and therapeutic prospects,” Journal of the
American Heart Association, vol. 8, pp. e013389–12, 2019.
[24] K.M. Hallow, G. Helmlinger, P. J. Greasley, J. J. V. McMurray,
and D. W. Boulton, “Why do SGLT2 inhibitors reduce heart
failure hospitalization? A differential volume regulation
hypothesis,” Diabetes, Obesity and Metabolism, vol. 20, no. 3,
pp. 479–487, 2018.
[25] K. Ohara, T. Masuda, M. Morinari et al., “'e extracellular
volume status predicts body fluid response to SGLT2 inhibitor
dapagliflozin in diabetic kidney disease,” Diabetology &
Metabolic Syndrome, vol. 12, no. 1, pp. 1–9, 2020.
[26] M. Griffin, V. S. Rao, J. Ivey-Miranda et al., “Empagliflozin in
heart failure,” Circulation, vol. 142, no. 11, pp. 1028–1039,
2020.
[27] C. J. Bailey, “Uric acid and the cardio-renal effects of SGLT2
inhibitors,” Diabetes, Obesity and Metabolism, vol. 21, no. 6,
pp. 1291–1298, 2019.
[28] R. Chilton, I. Tikkanen, C. P. Cannon et al., “Effects of
empagliflozin on blood pressure and markers of arterial
stiffness and vascular resistance in patients with type 2 dia-
betes,” Diabetes, Obesity and Metabolism, vol. 17, no. 12,
pp. 1180–1193, 2015.
[29] M. Packer, “SGLT2 inhibitors produce cardiorenal benefits by
promoting adaptive cellular reprogramming to induce a state
of fasting mimicry: A paradigm shift in understanding their
mechanism of action,” Diabetes Care, vol. 43, no. 3,
pp. 508–511, 2020.
[30] H. Zhou, S. Wang, P. Zhu, S. Hu, Y. Chen, and J. Ren,
“Empagliflozin rescues diabetic myocardial microvascular
injury via AMPK-mediated inhibition of mitochondrial fis-
sion,” Redox Biology, vol. 15, pp. 335–346, 2018.
[31] S. E. Inzucchi, B. Zinman, D. Fitchett et al., “How does
empagliflozin reduce cardiovascular mortality? Insights from
a mediation analysis of the EMPA-REG OUTCOME trial,”
Diabetes Care, vol. 41, no. 2, pp. 356–363, 2018, http://care.
diabetesjournals.org/lookup/suppl/http://www.
diabetesjournals.org/content/diabetes-core-update-podcasts.
[32] J. Li, M. Woodward, V. Perkovic et al., “Mediators of the
effects of canagliflozin on heart failure in patients with type 2
diabetes,” Journal of the American College of Cardiology: Heart
Failure, vol. 8, no. 1, pp. 57–66, 2020.
[33] H. J. L. Heerspink, B. A. Perkins, D. H. Fitchett, M. Husain,
and D. Z. I. Cherney, “Sodium glucose cotransporter 2 in-
hibitors in the treatment of diabetes mellitus,” Circulation,
vol. 134, no. 10, pp. 752–772, 2016.
[34] S. Kang, S. Verma, A. F. Hassanabad et al., “Direct effects of
empagliflozin on extracellular matrix remodelling in human
cardiac myofibroblasts: Novel translational clues to explain
EMPA-REG OUTCOME results,” Canadian Journal of Car-
diology, vol. 36, no. 4, pp. 543–553, 2020.
[35] T.-M. Lee, N.-C. Chang, and S.-Z. Lin, “Dapagliflozin, a se-
lective SGLT2 Inhibitor, attenuated cardiac fibrosis by reg-
ulating the macrophage polarization via STAT3 signaling in
infarcted rat hearts,” Free Radical Biology and Medicine,
vol. 104, pp. 298–310, 2017.
[36] T. Mason, O. R. Coelho-Filho, S. Verma et al., “Empagliflozin
reduces myocardial extracellular volume in patients with type
2 diabetes and coronary artery disease,” JACC Cardiovasc
Imaging, vol. 14, no. 6, 2021.
Cardiology Research and Practice 11
